Literature DB >> 3087158

Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia.

A Salama, V Kiefel, C Mueller-Eckhardt.   

Abstract

Seventeen adult patients with chronic (15 cases) or acute (two cases) autoimmune thrombocytopenia (ITP) were given intravenous and/or intramuscular injections of 0.75-4.5 mg of IgG anti-Rho(D) over a period of 1-5 days. Significant elevations of the platelet count (increments greater than 50 X 10(9)/liter) resulted in 13 of 15 Rh-positive patients but not in either of two Rh-negative patients. Heat-aggregated human albumin given to one of the Rh-negative patients also did not lead to a significant increase of the platelet count. The elevation of the platelet counts in Rh-positive patients after IgG anti-Rho(D) administration was often transient (less than 4 weeks), but long-term benefit (greater than 5 months) was achieved in five cases. The IgG concentration on RBC from five Rh-positive patients studied increased from a usually undetectable value before to approximately 700-1,700 IgG molecules/per RBC after anti-Rho(D) administration resulting in a strongly positive direct antiglobulin test. Nevertheless, an overt clinical hemolysis was seen in only one patient. The clearance of autologous 51Cr-labeled RBC was determined in four patients and was slightly enhanced in three and normal in one splenectomized patient. We conclude that the Fc receptor blockade involved in platelet sequestration was not associated with the induction of significant RBC clearance and that a reversible interaction of sensitized RBC with phagocytic cells and/or a low-grade destruction of these cells might be sufficient for the elevation of circulating platelets in the majority of patients with ITP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087158     DOI: 10.1002/ajh.2830220304

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  A therapy-refractory neonatal auto-immune thrombocytopenia treated with anti-D.

Authors:  Gerhard Gaedicke; Malte Cremer; Oliver Meyer; Abdulgabar Salama
Journal:  Eur J Pediatr       Date:  2003-12-23       Impact factor: 3.183

Review 3.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Intravenous IgG: A New Therapeutic Tool.

Authors:  L K Boshkov; J G Kelton
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

5.  Management of ITP with immunoglobulin anti-Rh0 (D)

Authors:  P Colomina; A Cervero; S García
Journal:  Blut       Date:  1989-09

6.  Immune phagocytosis inhibition by commercial immunoglobulins.

Authors:  J Neppert; M Clemens; C Mueller-Eckhardt
Journal:  Blut       Date:  1986-02

Review 7.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 8.  The nontreatment of childhood idiopathic thrombocytopenic purpura.

Authors:  G R Buchanan
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

9.  Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.

Authors:  Eric Cheung; Howard A Liebman
Journal:  Biologics       Date:  2009-07-13

Review 10.  Intravenous immunoglobulin and Alzheimer's disease: what now?

Authors:  David A Loeffler
Journal:  J Neuroinflammation       Date:  2013-06-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.